RxDoctor Payments Data

Leibe Arroyave Smilovitz, MD

Internal Medicine · Aventura, FLNPI 1447819735

Payments from drug & device makers

$3,786in general payments, 2019–2025

Across 172 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$499
  • GSK$456
  • Amgen$430
  • AstraZeneca$412
  • Boehringer Ingelheim$312
  • Astellas Pharma US Inc$216
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,69298%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,786 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$2,840
Medicare patients
18
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$65,545
JardianceEmpagliflozin42$47,213
MounjaroTirzepatide41$42,480
OzempicSemaglutide25$37,255
JanuviaSitagliptin Phosphate25$27,778
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$20,754
XareltoRivaroxaban16$19,569
LinzessLinaclotide18$14,354
SymbicortBudesonide/Formoterol Fumarate23$6,436
Rosuvastatin Calcium218$2,968
Losartan Potassium212$2,208
Atorvastatin Calcium198$1,842
Albuterol Sulfate HfaAlbuterol Sulfate51$1,587
Levothyroxine Sodium166$1,512
Gabapentin113$1,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$158$65,54558 claims
Boehringer IngelheimJardiance$312$47,21342 claims
Lilly USA, LLCMounjaro$499$42,48041 claims
Novo NordiskOzempic$161$37,25525 claims
GSKTrelegy Ellipta$456$20,75421 claims
Johnson & JohnsonXarelto$141$19,56916 claims
AbbVieLinzess, Synthroid$64$15,49431 claims
AstraZenecaSymbicort$412$6,43623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →